James C Hamilton sold $2.5M of ARWR
Chief Medical Officer at ARROWHEAD PHARMACEUTICALS, INC.. 40,164 shares at an average of $63.11, traded Jan 5, 2026, filed Jan 5, 2026.
Score components
- +15RoleOfficer
- +25Trade size$2.5M at market
- +5Share of holdings soldSold 19% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001830755-26-000002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 5, 2026 | SOpen-market sale Common Stock10b5-1 | -4,625 | $61.24 | $283k | 207,497 | Jan 5, 2026 |
| Jan 5, 2026 | SOpen-market sale Common Stock10b5-1 | -6,090 | $62.28 | $379k | 201,407 | Jan 5, 2026 |
| Jan 5, 2026 | SOpen-market sale Common Stock10b5-1 | -14,792 | $63.01 | $932k | 186,615 | Jan 5, 2026 |
| Jan 5, 2026 | SOpen-market sale Common Stock10b5-1 | -12,711 | $63.95 | $813k | 173,904 | Jan 5, 2026 |
| Jan 5, 2026 | SOpen-market sale Common Stock10b5-1 | -1,200 | $64.49 | $77k | 172,704 | Jan 5, 2026 |
| Jan 5, 2026 | SOpen-market sale Common Stock10b5-1 | -437 | $65.97 | $29k | 172,267 | Jan 5, 2026 |
| Jan 5, 2026 | SOpen-market sale Common Stock10b5-1 | -309 | $68.00 | $21k | 171,958 | Jan 5, 2026 |
Related signals
Other insiders at ARROWHEAD PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 8Weak | ARROWHEAD PHARMACEUTICALS, INC. | Hongbo Lu director | $228k 2,970 shares | -5% | |
| 34Weak | ARROWHEAD PHARMACEUTICALS, INC. | Daniel Joseph Apel Chief Financial Officer | $934k 13,095 shares | -7% | |
| 25Weak | ARROWHEAD PHARMACEUTICALS, INC. | James C Hamilton Chief Medical Officer | $750k 10,000 shares | -4% | |
| 15Weak | ARROWHEAD PHARMACEUTICALS, INC. | James C Hamilton Chief Medical Officer | $642k 10,000 shares | -4% | |
| 43Moderate | ARROWHEAD PHARMACEUTICALS, INC. | Christopher Richard Anzalone Chief Executive Officer | $872k 13,187 shares | -0% | |
| 40Moderate | ARROWHEAD PHARMACEUTICALS, INC. | Patrick O'Brien COO | $3.1M 49,493 shares | -9% | |
| 30Weak | ARROWHEAD PHARMACEUTICALS, INC. | Christopher Richard Anzalone Chief Executive Officer | $3.6M 51,726 shares | -1% | |
| 28Weak | ARROWHEAD PHARMACEUTICALS, INC. | Mauro Ferrari director | $527k 7,530 shares | -10% | |
| 35Weak | ARROWHEAD PHARMACEUTICALS, INC. | Adeoye Y Olukotun director | $677k 10,000 shares | -23% | |
| 45Moderate | ARROWHEAD PHARMACEUTICALS, INC. | Christopher Richard Anzalone Chief Executive Officer | $1.8M 26,031 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.